Adagio Therapeutics总结了ADG20对新冠病毒变种的中和活性，并概述了应对奥密克戎的举措
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
几家独立实验室最近发表的文章表明，ADG20具有中和活性，其效力可与其他针对奥密克戎的保有活性抗体相媲美 目前正在进行多项努力来应对奥密克戎和潜在的新冠病毒变种 马萨诸塞州沃尔瑟姆, Jan. 14, 2022 (GLOBE NEWSWIRE) -- 专注于发现、开发和商业化具有疫情潜力传染病抗体解决方案的临床阶段生物制药公司Adagio Therapeutics,...
Adagio Therapeutics resume actividad neutralizante de ADG20 contra variantes de SARS-CoV-2 y describe iniciativas para abordar la variante ómicron
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
Publicaciones recientes de varios laboratorios independientes muestran que ADG20 tiene actividad neutralizante con potencia comparable a otros anticuerpos que retienen actividad contra la variante...
Adagio Therapeutics Meringkaskan Aktiviti Peneutralan ADG20 Terhadap Varian SARS-CoV-2 dan Menggariskan Inisiatif Menangani Omicron
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
Penerbitan Terkini oleh Beberapa Makmal Bebas Menunjukkan ADG20 Mempunyai Aktiviti Yang Meneutralkan dengan Potensi Setanding dengan Antibodi Lain yang Mengekalkan Aktiviti Melawan Omicron Pelbagai...
Adagio Therapeutics, SARS-CoV-2 변이에 대한 ADG20의 중화 활동 종합 보고 및 Omicron 대응 계획 발표
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
여러 독립 시험기관의 연구 결과, ADG20의 중화 활동 능력치는 Omicron 중화 활동 보유한 기타 항체에 필적할 수준 Omicron 및 기타 SARS-CoV-2 변이 가능성에 대처하기 위해 다각도로 노력 중 미국 매사추세츠주 월섬, Jan. 14, 2022 (GLOBE NEWSWIRE) -- 임상 단계 바이오 제약사로 팬데믹으로 변질 우려가...
Adagio Therapeutics legt zusammenfassende Ergebnisse zur neutralisierenden Wirkung von ADG20 gegenüber SARS-CoV-2-Varianten vor und stellt Initiativen zur Bekämpfung von Omikron vor
13 janv. 2022 19h30 HE
|
Adagio Therapeutics, Inc.
Aktuelle Veröffentlichungen verschiedener unabhängiger Labore bestätigen, dass die neutralisierende Wirkung von ADG20 mit anderen Antikörpern vergleichbar ist, die die Aktivität gegen Omikron...
Online Festivals Soar, Omicron Surges, and Sundance goes Full Stream Ahead
13 janv. 2022 14h53 HE
|
Shift72
HAMILTON, New Zealand, Jan. 13, 2022 (GLOBE NEWSWIRE) -- With Omicron cases surging to record highs, Shift72 is seeing an influx in enquiries from global film festivals who are seeking – or...
MAKO Medical Exceeds 10 Million COVID-19 Tests
10 janv. 2022 06h30 HE
|
MAKO Medical
Raleigh, North Carolina, Jan. 10, 2022 (GLOBE NEWSWIRE) -- MAKO Medical Laboratories, a national reference laboratory and leader in COVID-19 testing, today announced that it has surpassed another...
First Wave BioPharma Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections
06 janv. 2022 07h00 HE
|
First Wave BioPharma, Inc.
No Drug-Related SAEs Reported; Topline Data Expected 1H 2022 Part 2 of RESERVOIR Trial to Evaluate Efficacy of FW-COV, an Oral Formulation of Niclosamide, and Expand Safety Observations on...
Expanding the Success of Famileo: Still Bringing Residents and Families Together!
05 janv. 2022 14h42 HE
|
Signature Healthcare
Louisville, KY., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Signature HealthCARE’s residents and families have been nothing short of resilient during our on-going pandemic in a number of ways, including...
First Wave BioPharma to Participate in Two Investor Conferences in January 2022
04 janv. 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 04, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...